First full, in-depth safety studies are accessible via the Bayer platform / Bayer reconfirms its commitment to transparency by supporting the European Commission’s call for greater transparency around crop protection safety studies
Monheim, March 13, 2018
– Bayer is proud to announce that its transparency initiative has entered the next phase. Full, in-depth, safety-related study reports can now be requested providing they are not used for commercial purpose. Bayer’s transparency platform, cropscience-transparency.bayer.com
demonstrates how transparency around crop protection safety studies can be improved, while at the same time safeguarding confidential business information.
“Bayer’s initiative leads the way regarding the transparency of crop protection studies. We welcome the European Commission’s plan to make industry studies more transparent while respecting the need to protect legitimate confidential business information,” says Dr. Adrian Percy, global head of Research and Development for the Crop Science Division. “It is critical to ensure that safety data is made available strictly for non-commercial use in order to protect and continue promoting innovation.”
The company offers its full support to the European Commission in finding practical solutions to make industry safety studies more accessible.
First announced in 2016, Bayer’s transparency initiative aims to break down barriers to build public trust and foster a fair, science-based dialogue around crop protection products. The platform was launched in 2017. Until now, mostly study summaries were available in addition to safety-related study reports on the active substance imidacloprid. Trust in the science used to ensure safety of its products is of vital importance to Bayer. With this in mind, Bayer sees its transparency initiative as a contribution to regain trust by the public and policy makers in regulatory science.About Bayer
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.